Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,245.99 -9.41 (-0.75%)

Streaming Delayed Price Updated: 2:29 PM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock. ↗

July 09, 2026

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

Via The Motley Fool

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗

July 09, 2026

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Via The Motley Fool

Topics ETFs

July 09, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

My Forever Portfolio: 5 Undervalued Stocks to Buy Now and Hold Forever ↗

July 08, 2026

Investing for the long-term requires a different strategy.

Via The Motley Fool

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? ↗

July 08, 2026

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

Via The Motley Fool

Topics ETFs

Is It Too Late to Buy Eli Lilly? ↗

July 08, 2026

The stock has soared 400% in recent years.

Via The Motley Fool

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗

July 08, 2026

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly

July 08, 2026

Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T...

Via StockStory

Topics Economy Electric Vehicles

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗

July 08, 2026

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Via The Motley Fool

Why Eli Lilly Stock Climbed to a Record High Today ↗

July 07, 2026

Wall Street is getting more bullish on the pharma giant's shares.

Via The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗

July 07, 2026

Don't sleep on these medical device leaders.

Via The Motley Fool

Topics Supply Chain

3 Reasons to Buy Novo Nordisk Stock ↗

July 07, 2026

The stock is down, but it isn't out yet.

Via The Motley Fool

Why Eli Lilly (LLY) Stock Is Trading Up Today

July 07, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri...

Via StockStory

U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗

July 07, 2026

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Via The Motley Fool

Warren Buffett Has Recommended 1 Investment for Decades -- but There's a Hidden Risk Many Investors Are Overlooking ↗

July 07, 2026

This key factor didn't exist when Buffett first gave the advice, but does that change its appeal?

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Eli Lilly's Market Cap Balloons Again On This IPO's Setback ↗

July 07, 2026

Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug.

Via Investor's Business Daily

Topics Initial Public Offering

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? ↗

July 07, 2026

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. ↗

July 07, 2026

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

Via The Motley Fool

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗

July 06, 2026

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Via MarketBeat

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 06, 2026

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Via The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗

July 06, 2026

Lilly offers investors safety and growth.

Via The Motley Fool

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗

July 05, 2026

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

Via The Motley Fool

Topics ETFs Intellectual Property

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗

July 05, 2026

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

Via The Motley Fool

Topics ETFs

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗

July 04, 2026

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

Via The Motley Fool

Topics ETFs

State Street Health Care ETF Tops Invesco Pharma on Cost and Size ↗

July 04, 2026

Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗

July 04, 2026

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

Via The Motley Fool

Topics ETFs

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗

July 04, 2026

Compare fees, diversification, and risk between these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.